Hongbin Chen, MD, PhD

Treating sensitizing EGFR-mutant non-small cell lung cancer (NSCLC) with tyrosine kinase inhibitors (TKIs) leads to better outcomes compared with standard chemotherapy.

Anti-angiogenic therapy aims to disrupt blood supply to tumors and has proven clinical benefit in nonsquamous non-small cell lung cancer (NSCLC).

Activating EGFR mutations are associated with response to TKIs. Afatinib (Gilotrif) is an oral, irreversible ErbB family TKI that targets EGFR, HER2, and ErbB4. Afatinib is being formally evaluated in the LUX-Lung clinical trial program for NSCLC.